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Summary: We conducted a genome-wide association study of subjective well-being (SWB) 
in 298,420 individuals. We also performed auxiliary analyses of depressive symptoms (“DS”; 
N = 161,460) and neuroticism (N = 170,910), both of which have a substantial genetic 
correlation with SWB (?̂? ≈ −0.8). We identify three SNPs associated with SWB at genome-
wide significance. Two of them are significantly associated with DS in an independent 
sample. In our auxiliary analyses, we identify 13 additional genome-wide-significant 
associations: two with DS and eleven with neuroticism, including two inversion 
polymorphisms. Across our phenotypes, loci regulating expression in central nervous system 
and adrenal/pancreas tissues are enriched. The discovery of genetic loci associated with the 
three phenotypes we study has proven elusive; our findings illustrate the payoffs from 
studying them jointly. 
 
One Sentence Summary: Using both genome-wide association studies and proxy-phenotype 
studies, we identify genetic variants associated with subjective well-being, depressive 
symptoms, and neuroticism. 
 
 
Main Text: Subjective well-being (SWB)—as measured by survey questions on life 
satisfaction, positive affect, or happiness—is a major topic of research within psychology, 
economics, and epidemiology and is the focus of policy initiatives instigated by many 
governments and international bodies (1–3). Twin studies suggest that roughly 35% of the 
variation in SWB across individuals can be explained by genetic factors (4). The discovery of 
genetic variants associated with SWB could pave the way for investigations into how 
environmental conditions moderate genetic effects. Moreover, it may provide insights not 
only into the molecular mechanisms underlying normal-range variation in SWB, but also 
those underlying genetically correlated phenotypes, such as depression and neuroticism (5–
7), for which the discovery of genetic associations has proven elusive (8, 9). 
Here, we report a series of analyses that exploit the relationships between SWB, depressive 
symptoms (DS), and neuroticism. Our primary analysis is a genome-wide association study 
(GWAS) of SWB based on data from 59 cohorts (N = 298,420). We supplement this primary 
analysis with auxiliary GWAS meta-analyses of DS and neuroticism. The auxiliary analyses 
are performed by combining publicly available summary statistics from published studies 
with new genome-wide analyses of additional data. All analyses in this paper are restricted to 
European-ancestry individuals.  
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Following a pre-specified analysis plan, our primary analysis combines survey measures of 
life satisfaction (LS) and positive affect (PA). Although LS and PA are distinguishable (10, 
11), these two facets of SWB are phenotypically correlated and load on a common genetic 
factor (12). To reduce measurement error, cohorts with repeated measures averaged 
responses, and cohorts with survey questions measuring both LS and PA combined the two 
measures into a single variable. For details on SWB phenotype construction, see tables S1.1 
and S2.1. 
All SWB analyses were performed at the cohort level and subsequently meta-analyzed. Our 
analysis plan specified controls for age, age2, sex, and (to reduce confounding from 
population stratification) four principal components of the genome-wide data (13). A uniform 
set of quality-control (QC) procedures, described in tables S2.3-2.4, were applied to the 
cohort-level summary statistics, including but not limited to the EasyQC protocol recently 
recommended (14). 
We conducted a sample-size-weighted meta-analysis of ~2.3M HapMap2 SNPs and adjusted 
the standard errors using the estimated intercept from an LD Score regression (15). The 
estimated intercept implies that a modest ~5% of the observed inflation in the unadjusted 
mean 𝜒2 is accounted for by bias rather than polygenic signal (fig. S3.1). The slope estimate 
implies that our phenotype has a SNP-based heritability estimate of 4.0% (SE = 0.2%; cf. 
(16)). 
In our primary analysis of SWB, we found three approximately independent genome-wide 
significant SNPs (hereafter “lead SNPs”). Fig. 1a shows the Manhattan plot from the main 
analysis. All three lead SNPs have estimated effects in the range 0.015 to 0.018 standard 
deviations (SDs) per allele (R2 ≈ 0.01%). For comparison, we calculated, using publicly 
available survey data from the U.S. Behavioral Risk Factor Surveillance System, that the 
average difference in SWB between “no” and “yes” responders to “ever diagnosed with a 
depressive disorder” is 0.66 SDs (table S1.2). We also conducted separate meta-analyses of 
LS (N = 166,205) and PA (N = 180,281), using procedures identical to those described above. 
Consistent with our theoretical calculations (fig. S4.1), these analyses yielded fewer signals 
across a range of p-value thresholds (table S2.6). We found two lead SNPs in the LS analyses 
(both distinct from the SWB lead-SNPs) and none in the PA analyses.  
In our auxiliary analysis of DS we combined publicly available results from a study 
performed by the Psychiatric Genomics Consortium (PGC) (17) with new results from 
analyses of the initial release of the U.K. Biobank data (UKB) and the Resource for Genetic 
Epidemiology Research on Aging (GERA) Cohort. In UKB (N = 105,739), our measure is 
constructed from responses to two questions about the frequency with which the respondent 
experienced feelings of hopelessness or depression in the past two weeks. The other cohorts 
have case-control data on major depressive disorder (GERA: Ncases = 7,231, Ncontrols = 49,316; 
PGC: Ncases = 9,240, Ncontrols = 9,519). In the DS meta-analysis, we weight UKB by sample 
size and the two case-control studies by effective sample size (18). 
In our auxiliary analysis of neuroticism (N = 170,910), we pooled summary statistics from a 
study by the Genetics of Personality Consortium (GPC) (8) with results from a new analysis 
of UKB data. In UKB, our measure is the respondent’s score on a 12-item version of the 
Eysenck Personality Inventory Neuroticism scale (19). The GPC harmonized different 
neuroticism batteries (table S5.2). 
Figs. 1b and 1c show the Manhattan plots. For DS, we identified two genome-wide 
significant SNPs. For neuroticism, our meta-analysis procedure yielded 16 seemingly-
independent genome-wide significant SNPs. However, 6 of these SNPs reside within a well-
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known inversion polymorphism on chromosome 8 (20). We established that all genome-wide 
significant signals in the inversion region are attributable to the inversion (fig. S6.3) and 
confirmed that the inversion is associated with neuroticism in both the GPC and UKB data. 
Another SNP, rs193236081, is located on a well-known inversion polymorphism on 
chromosome 17, and we also established that this association is attributable to the inversion 
polymorphism (fig S6.6). However, because this inversion yields only one significant SNP 
and is genetically complex (21), we hereafter simply use rs193236081 as its proxy. Our 
neuroticism GWAS therefore identified 9 lead SNPs and 2 inversion polymorphisms. A 
concurrent, unpublished neuroticism GWAS using overlapping data reports similar findings 
(22). 
The estimated effects of the genome-wide significant associations on DS and neuroticism are 
similar, with coefficient estimates in the range 0.020 to 0.031 SDs per allele (R2 ≈ 0.02%). In 
the UKB cohort we estimated the effect of an additional allele of the chromosome 8 inversion 
polymorphism on neuroticism to be 0.035 SDs. For the 16 polymorphisms identified across 
our main and auxiliary analyses—three for SWB, two for DS, and eleven for neuroticism—
Bayesian analyses show that for a wide range of priors, the evidence for association is highly 
credible (fig. S7.1). 
In independent samples, a polygenic score constructed from our primary SWB GWAS results 
explains ~0.9% of the variance in SWB, ~0.5% in DS, and ~0.7% in neuroticism (table S8.1). 
Applying bivariate LD Score regression (23) to our GWAS results, we found substantial 
pairwise genetic correlations between SWB and our two auxiliary phenotypes: -0.81 (SE = 
0.046) for DS (cf., (24)) and -0.75 (SE = 0.034) for neuroticism (table S9.1). As a placebo 
test, we also examined height, which we expected to have much less genetic overlap with 
SWB (25). Indeed, we find that the polygenic score explains ~0.2% of the variance in height, 
and the genetic correlation with SWB is only 0.07 (SE = 0.028).   
Motivated by this evidence of genetic overlap with DS and neuroticism, which is in line with 
large genetic correlations estimated from twin-family studies (5, 6), we conducted a series of 
“quasi-replication” exercises in which we examined whether (i) the three genome-wide 
significant SNPs in the SWB analyses are associated with DS and neuroticism, and (ii) the 
genome-wide significant hits found in the auxiliary GWAS analyses of DS and neuroticism 
are associated with SWB. To avoid sample overlap, the analyses of the “second-stage” 
phenotype were always restricted to cohorts that did not contribute to the “first-stage” 
analysis.  
Fig. 2 illustrates the results from these analyses. For interpretational ease, we choose 
reference alleles so that each SNP’s estimated effect on SWB is negative; that way, its 
predicted effect on DS and neuroticism is positive. Panel A shows that two out of the three 
SWB lead-SNPs are significantly associated with DS in the predicted direction (p = 0.004 
and p = 0.001), and the third has the opposite sign and is not significantly associated with DS. 
For neuroticism, the SWB-increasing allele has the predicted sign for all three SNPs, but 
none reach significance (Panel B). Panel C shows that the two DS lead-SNPs have the 
predicted sign for SWB, and one is nominally significant (p = 0.04). Finally, of the eleven 
polymorphisms associated with neuroticism, four have the predicted sign and are 
significantly associated with SWB, five have the predicted sign and are not significantly 
associated with SWB, and two have the opposite sign and are not significantly associated 
with SWB (Panel D). One of the four significant polymorphisms is the SNP tagging the 
inversion on chromosome 8 (20). That SNP’s association with neuroticism (and likely with 
SWB) is driven by its correlation with the inversion (fig. S6.3). 
. CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/032789doi: bioRxiv preprint first posted online Nov. 24, 2015; 
4 
  
Because of the strong genetic correlation between SWB and DS, the two successful quasi-
replications of the SWB lead-SNPs for DS lend credibility to their truly being associated with 
both SWB and DS. Indeed, our formal Bayesian calculations (table S11.1) show that for each 
SNP’s effect on each phenotype, we can exclude a zero effect size with greater than 95% 
probability. Similarly, across the 19 quasi-replication attempts depicted in fig. 2, with at least 
95% probability we can exclude a zero effect size for 18 of the first-stage effects and 9 of the 
second-stage effects. This Bayesian analysis also yields effect-size estimates that are 
corrected for the winner’s curse: relative to the initial estimates, on average these estimates 
are smaller by a factor of four for the first-stage phenotype and two for the second-stage 
phenotype. 
We also conducted two similar “proxy-phenotype” analyses (26). We examine whether the 
independent SNPs associated with SWB at p < 10-4 and available in the second-stage 
sample—163 SNPs for DS and 170 for neuroticism—are enriched for association with DS 
and neuroticism. For both second-stage phenotypes, the observed level of enrichment is 
stronger than the expected level of enrichment for a randomly drawn set of SNPs matched on 
allele frequency and second-stage sample size (p < 3×10-5 and p < 0.04, respectively). For 
DS, 116 out of 163 SNPs (71%) have the predicted direction of effect. Twenty of the 163 
SNPs are significantly associated with DS at the 5% level (19 with the predicted direction), 
and 2 remain significant after Bonferroni correction (fig. S10.1). For neuroticism, 129 out of 
170 SNPs (76%) have the predicted direction of effect, all 28 significant SNPs have the 
predicted sign, and 4 remain significant after Bonferroni correction (fig. S10.2). As a placebo 
test, we also test SWB-associated SNPs for enriched association with height. In stark contrast 
to what we find for DS and neuroticism, we find no evidence for enrichment and cannot 
reject the null hypothesis that the effects have the predicted sign only 50% of the time (25). 
Table 1 gives a summary overview of the SNPs identified across our analyses. In the upper 
panel, we list all lead SNPs from the meta-analyses of SWB, DS, or neuroticism, and we 
indicate which have significant associations in the quasi-replication analyses. In the lower 
panel, we list the SNPs identified in the proxy-phenotype analyses. For each SNP, we report 
its estimated effect. Finally, we also report if each SNP (or a variant in strong linkage 
disequilibrium with that SNP) is (i) nonsynonymous (i.e., alters the protein product) or is (ii) 
an eQTL (i.e., affects the extent to which certain genes are expressed), and we report (iii) the 
nearest protein-coding gene; for details, see tables S2.6, S10.2-10.3, S12.5-12.6, and S12.8. 
We further investigated the biological mechanisms underlying the GWAS results by applying 
stratified LD Score regression (27) to our meta-analysis results. The method takes as given 
some categorization of SNPs, and for each category, it estimates the expected increase in the 
explanatory power of a SNP due to its being in that category. In our first analysis, we report 
estimates for all 53 functional categories included in the “baseline model” (tables S12.1-
12.3); the results for SWB, DS, and neuroticism are broadly similar and are in line with what 
has been found for other phenotypes (27). In our second analysis, the categories are 
groupings of SNPs likely to regulate gene expression in cells of a specific tissue. The 
estimates for SWB, DS, and neuroticism are shown in fig. 3a. As a benchmark, we also 
provide results from the GIANT consortium’s most recent study of height (28). The height 
results are clearly distinguished by the much higher estimates for the categories 
CONNECTIVE/BONE, CARDIOVASCULAR, and SKELETAL MUSCLE. In contrast, the estimates for 
the category CENTRAL NERVOUS SYSTEM are significantly positive for all three of our 
phenotypes, and the estimates for ADRENAL/PANCREAS for two of the three, SWB and DS. 
This latter result is in line with previous research on the role of hypothalamic-pituitary-
adrenal (HPA)-axis in depressed patients (29). 
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We also investigated potential molecular mechanisms underlying the effects of the inversion 
on chromosome 8. The chromosome 8 inversion, and the 7 genes for which we find the 
inversion is a significant cis-eQTL at FDR < 0.05, are depicted in fig. 3b. The fact that these 
genes are all positioned in close proximity to the inversion breakpoints suggests that the 
molecular mechanism could involve the relocation of regulatory sequences. Three of the 
genes (FDFT1, MSRA, MTMR9) are known to be highly expressed in tissues and cell types 
that belong to the central nervous system, and two (BLK, MFHAS1) in the immune system. 
To summarize, we report a number of credible genetic associations with our primary 
phenotype of SWB as well as our auxiliary phenotypes of DS and neuroticism. The small 
effect sizes help shed light on why earlier studies of these phenotypes have had limited 
success. For example, given our winner’s-curse-adjusted estimates of the effect sizes, we 
calculate that the power for detecting the genome-wide significant SNPs from our analysis in 
the largest previous GWAS of depression and neuroticism was only ~0.012% and 
~0.00005%, respectively (table S11.2). 
Our study found many more credible associations than prior work due to two strategies. First, 
our GWAS had much larger sample sizes. Our findings support the view that GWAS can 
succeed even for highly polygenic phenotypes once sample sizes are large enough (9, 30). 
Second, our proxy-phenotype strategy exploited the strong genetic overlap between SWB, 
depression, and neuroticism. We anticipate that future efforts to identify genetic variants 
associated with these phenotypes could similarly benefit from studying them in concert. 
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Fig. 1. Manhattan plots. (A) Subjective well-being (N = 298,420), (B) Depressive symptoms (Neff = 149,707), (C) Neuroticism (N = 170,911). 
The x-axis is chromosomal position, and the y-axis is the significance on a −log10 scale. The upper dashed line marks the threshold for genome-
wide significance (p = 5×10-8); the lower line marks the threshold for nominal significance (p = 10-5). Each independent genome-wide 
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Fig. 2. Quasi-replication of lead SNPs. We examined whether (i) lead SNPs identified in the SWB meta-analyses are associated with DS and 
neuroticism, and (ii) lead SNPs identified in the analyses of DS and neuroticism are associated with SWB. The quasi-replication sample is 
always restricted to non-overlapping cohorts. The bars represent 95% CIs (not adjusted for multiple testing). The sample sizes (maximum across 
SNPs) are: (A) SWB (N = 294,043) → DS (Neff = 123,506), (B) SWB (N = 294,043) → Neuroticism (N = 68,201), (C) DS (Neff = 124,498) → 
SWB (N = 238,254), (D) Neuroticism (N = 170,908) → SWB (N = 198,360). For interpretational ease, we choose the reference allele so that 
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Fig. 3. Results from selected biological analyses. (A) Estimates of the expected increase in 
the phenotypic variance accounted for by a SNP due to the SNP’s being in a given category 
(𝜏𝑐), divided by the LD Score heritability of the phenotype (ℎ
2). Each estimate of 𝜏𝑐 comes 
from a separate stratified LD Score regression, controlling for the 52 functional annotation 
categories in the “baseline model.” The bars represent 95% CIs (not adjusted for multiple 
testing). To benchmark the estimates, we compare them to those obtained from a recent study 
of height (28). (B) Inversion polymorphism on chromosome 8 and the 7 genes for which the 
inversion is a significant cis-eQTL at FDR < 0.05. The upper half of the figure shows the 
Manhattan plot for neuroticism for the inversion and surrounding regions. The bottom half 
shows the squared correlation between the SNPs and the principal component that captures 
the inversion. The inlay plots the relationship, for each SNP in the inversion region, between 
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Table 1. Summary Overview of Polymorphisms Identified Across Analyses. All effect 
sizes are reported in units of SDs per allele. “Q-rep”: Whether SWB lead-SNP quasi-
replicated in DS or neuroticism, and whether DS/neuroticism lead-SNP quasi-replicated in 
SWB, all at p < 0.05. “Location”: type of genomic region according to dbsnp and Ensembl. 
“Non-syn”: Whether the SNP or any LD partner (R2 ≥ 0.6 and within 250kb) is non-
synonymous according to HaploReg (version 4). “eQTL”: Whether the SNP is a cis-eQTL in 
whole blood (at FDR < 0.05). “Nearest protein-coding gene”: The nearest-protein coding 
gene (5’ start site) of the lead SNP according to GENCODE coordinates archived at 
http://www.broadinstitute.org/mpg/snpsnap/. Proxy SNP rs4346787 (R2 = 0.98) was used to 
tag rs4481363 in the DS data. All details are in SOM Section 12.2. 
* Note:  rs10960103 tags the inversion polymorphism on chromosome 8. 
 
Panel A. Genome-Wide Significant Associations 
 
SWB (N = 298,420) 
SNP Beta SE p-value Q-rep Location Non-syn eQTL Nearest protein 
-coding gene 
rs3756290 -0.0177 0.0031 9.55×10-9  intronic  Y RAPGEF6 
rs2075677 0.0175 0.0031 1.49×10-8 DS intronic Y Y CSE1L 
rs4958581 0.0153 0.0028 2.29×10-8 DS intronic   NMUR2 
  
DS (N = 161,460) 
rs7973260 0.0306 0.0051 1.78×10-9  intronic  Y KSR2 
rs62100776 -0.0252 0.0044 8.45×10-9 SWB intronic   DCC 
         
Neuroticism (N = 107,245) 
rs2572431 0.0283 0.0035 4.20×10-16  intergenic  Y MTMR9 
rs193236081 -0.0284 0.0043 6.26×10-11  intronic Y Y KANSL1 
rs10960103* 0.0264 0.0042 2.14×10-10 SWB intergenic   TYRP1 
rs4938021 0.0233 0.0337 4.03×10-10  intergenic   DRD2 
rs139237746 -0.0204 0.0034 2.55×10-9 SWB intronic  Y SBF2 
rs1557341 0.0213 0.0036 5.58×10-9  intronic   CELF4 
rs12938775 -0.0202 0.0035 8.54×10-9 SWB intronic   PAFAH1B1 
rs12961969 0.0253 0.0045 2.16×10-8  intergenic   CELF4 
rs35688236 0.0213 0.0038 2.35×10-8  intronic   PDCD6IP 
rs2150462 -0.0217 0.0039 2.66×10-8 SWB intergenic   ELAVL2 
rs12903563 0.0198 0.0036 2.86×10-8  intronic   LINGO1 
  
 
Panel B. Additional DS and Neuroticism SNPs Identified Via Proxy-Phenotype Analysis 
 
SWB (N = 278,956) → DS (Neff = 111,106) 
SNP BetaDS SEDS p-valueDS Location Non-syn eQTL Nearest protein 
-coding gene 
rs4481363 0.0136 0.0038 3.06×10-4 intronic   ZNF184 
rs6904596 -0.023 0.0059 9.79×10-5 exonic  Y MAT2B 
        
SWB (N = 239,982) → Neuroticism (N = 131,867) 
SNP BetaNeur SENeur p-valueNeur Location Non-syn eQTL Nearest protein 
-coding gene 
rs4481363 0.0151 0.0040 1.86×10-4 intronic   ZNF184 
rs6904596 -0.0264 0.0072 2.49×10-4 exonic  Y MAT2B 
rs10838738 0.0178 0.0039 5.03×10-6 intronic  Y MTCH2 
rs10774909  -0.015 0.0039 1.20×10-4 intronic   NOS1 
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